Drugs / BI 14332 CL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02212925 | Nov 2006 → Mar 2007 | type 2 diabetes mellitus | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02212938 | Sep → Nov 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02211989 | Feb → Apr 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 14332 CL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02212938 ↗ |
| Action | Inhibit | “DPP-4 Inhibition” NCT02212925 ↗ |
| Route | Oral | “Single Rising Oral Doses of BI 14332 CL” NCT02211989 ↗ |